BRPI0312398B8 - derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído - Google Patents

derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído

Info

Publication number
BRPI0312398B8
BRPI0312398B8 BRPI0312398A BR0312398A BRPI0312398B8 BR PI0312398 B8 BRPI0312398 B8 BR PI0312398B8 BR PI0312398 A BRPI0312398 A BR PI0312398A BR 0312398 A BR0312398 A BR 0312398A BR PI0312398 B8 BRPI0312398 B8 BR PI0312398B8
Authority
BR
Brazil
Prior art keywords
diphenylprop
substituted
derivative
pharmaceutical composition
preparing compounds
Prior art date
Application number
BRPI0312398A
Other languages
English (en)
Other versions
BR0312398A (pt
BRPI0312398B1 (pt
Inventor
Najib Jamila
Caumont-Bertrand Karine
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR0312398A publication Critical patent/BR0312398A/pt
Publication of BRPI0312398B1 publication Critical patent/BRPI0312398B1/pt
Publication of BRPI0312398B8 publication Critical patent/BRPI0312398B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

"derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído". a presente invenção refere-se a novos derivados de 1,3-difenilprop-2-en-1-ona substituídos, composições farmacêuticas que os compreendem, suas aplicações em terapêutica, notadamente para o tratamento da isquemia cerebral. ela igualmente trata de um processo de preparação desses derivados.
BRPI0312398A 2002-07-08 2003-07-08 derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído BRPI0312398B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208571A FR2841900B1 (fr) 2002-07-08 2002-07-08 Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
PCT/FR2003/002127 WO2004005233A1 (fr) 2002-07-08 2003-07-08 Derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations

Publications (3)

Publication Number Publication Date
BR0312398A BR0312398A (pt) 2005-04-12
BRPI0312398B1 BRPI0312398B1 (pt) 2016-11-08
BRPI0312398B8 true BRPI0312398B8 (pt) 2021-05-25

Family

ID=29725283

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312398A BRPI0312398B8 (pt) 2002-07-08 2003-07-08 derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído

Country Status (24)

Country Link
US (3) US7943661B2 (pt)
EP (1) EP1525177B1 (pt)
JP (1) JP4575771B2 (pt)
KR (1) KR100974577B1 (pt)
CN (1) CN100548960C (pt)
AT (1) ATE365703T1 (pt)
AU (1) AU2003264698B2 (pt)
BR (1) BRPI0312398B8 (pt)
CA (1) CA2490986C (pt)
CY (1) CY1108085T1 (pt)
DE (1) DE60314633T2 (pt)
DK (1) DK1525177T3 (pt)
EA (1) EA011090B1 (pt)
ES (1) ES2287528T3 (pt)
FR (1) FR2841900B1 (pt)
IL (2) IL165696A0 (pt)
MX (1) MXPA05000427A (pt)
NO (1) NO329700B1 (pt)
NZ (1) NZ538051A (pt)
PL (1) PL207362B1 (pt)
PT (1) PT1525177E (pt)
SI (1) SI1525177T1 (pt)
WO (1) WO2004005233A1 (pt)
ZA (1) ZA200501082B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
JP2007517841A (ja) * 2004-01-08 2007-07-05 ジェンフィット １，３−ジフェニルプロプ−２−エン−１−オン誘導体化合物、その調製方法およびその使用
FR2902789A1 (fr) 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
TR201810393T4 (tr) * 2009-11-26 2018-08-27 Genfit Karaciğer rahatıszlıklarının tedavisi için 1,3-difenilprop-2-en-1-on türevlerinin kullanımı.
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
ES2656330T3 (es) 2010-05-17 2018-02-26 Genfit Preparación mejorada de derivados de chalcona
TWI415600B (zh) * 2011-08-10 2013-11-21 Univ Kaohsiung Medical 用於治療動脈粥狀硬化的組合物及其製備方法
AU2012360796B2 (en) 2011-12-28 2017-02-02 Genfit 1,3-diphenylpropane derivatives, preparations and uses thereof
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
AU2014206781B2 (en) 2013-01-18 2018-08-23 Genfit Methods of treatment of fibrosis and cancers
WO2017143038A1 (en) * 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
JP7010836B2 (ja) * 2016-03-31 2022-01-26 ジェンフィ 胆汁鬱滞性疾患の処置の方法
FR3056909B1 (fr) 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
FR3056908B1 (fr) 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CA3047098A1 (en) * 2016-12-16 2018-06-21 Jia Zhou Inhibitors of bromodomain-containing protein 4 (brd4)
CN110312705B (zh) * 2017-01-22 2021-07-09 苏州科睿思制药有限公司 Gft-505的晶型及其制备方法和用途
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
EP3585384A1 (en) 2017-02-24 2020-01-01 Genfit Pharmaceutical compositions for combination therapy
WO2018193007A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CN108658908B (zh) 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
CA3071202A1 (en) 2017-08-04 2019-02-07 Advitech Advisory And Technologies Sa Process for the preparation of elafibranor and novel synthesis intermediates
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
EP3710425A1 (en) 2017-11-16 2020-09-23 Teva Pharmaceuticals International GmbH Solid state forms of elafibranor
US11332457B2 (en) 2017-11-30 2022-05-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition and use thereof
EP3514541A1 (de) 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
WO2019186410A1 (en) * 2018-03-27 2019-10-03 Lupin Limited Solid forms of elafibranor and processes thereof
CN112513003A (zh) * 2018-08-03 2021-03-16 基恩菲特公司 伊拉非诺盐
WO2020039297A1 (en) * 2018-08-24 2020-02-27 Mankind Pharma Ltd. Novel compounds and their use in preparation of elafibranor and pharmaceutical acceptable salts thereof
WO2020115628A1 (en) * 2018-12-03 2020-06-11 Mankind Pharma Ltd. Solid forms of elafibranor and process of preparation thereof
CN110156648A (zh) * 2019-05-30 2019-08-23 河北科技大学 一种Elafibranor中间体的制备方法
CN114630660A (zh) 2019-10-28 2022-06-14 基恩菲特公司 具有抗氧化特性的联合疗法
CN112824380A (zh) * 2019-11-21 2021-05-21 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
CN111138264B (zh) * 2019-11-29 2023-08-04 温州医科大学 一种丁香醛衍生物及其在制备抗妇科肿瘤药物中的应用
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法
KR20220140760A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노의 다형체
KR20230011958A (ko) 2020-05-18 2023-01-25 장피트 원발성 경화성 담관염의 치료를 위한 엘라피브라노
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN113230240B (zh) * 2021-03-22 2022-12-27 广州医科大学 1,3-二苯基丙-2-烯-1-酮衍生物及其应用
CN114853686B (zh) 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) * 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (pt) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) * 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) * 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
DE68915269T2 (de) * 1988-11-25 1994-09-29 Dainippon Ink & Chemicals Polyvalentes entzündungshemmendes mittel.
JPH0442229A (ja) * 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CN1327384A (zh) 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
EP1254658B1 (en) * 2000-01-27 2008-09-24 Takara Bio Inc. Remedies for the treatment of nerve diorders
EP1330448A2 (en) * 2000-06-20 2003-07-30 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
JP2007517841A (ja) * 2004-01-08 2007-07-05 ジェンフィット １，３−ジフェニルプロプ−２−エン−１−オン誘導体化合物、その調製方法およびその使用

Also Published As

Publication number Publication date
KR100974577B1 (ko) 2010-08-06
ATE365703T1 (de) 2007-07-15
US20110190515A1 (en) 2011-08-04
CN100548960C (zh) 2009-10-14
MXPA05000427A (es) 2005-09-30
US20050176808A1 (en) 2005-08-11
WO2004005233A1 (fr) 2004-01-15
NO329700B1 (no) 2010-12-06
NZ538051A (en) 2007-11-30
US20070032543A1 (en) 2007-02-08
EP1525177B1 (fr) 2007-06-27
SI1525177T1 (sl) 2007-10-31
KR20050025327A (ko) 2005-03-14
PL372809A1 (en) 2005-08-08
JP2005532385A (ja) 2005-10-27
AU2003264698A1 (en) 2004-01-23
ES2287528T3 (es) 2007-12-16
JP4575771B2 (ja) 2010-11-04
CY1108085T1 (el) 2014-02-12
IL165696A (en) 2012-09-24
AU2003264698B2 (en) 2009-09-17
CA2490986A1 (fr) 2004-01-15
BR0312398A (pt) 2005-04-12
US7566737B2 (en) 2009-07-28
US8058308B2 (en) 2011-11-15
FR2841900B1 (fr) 2007-03-02
DE60314633T2 (de) 2008-02-28
EA011090B1 (ru) 2008-12-30
EP1525177A1 (fr) 2005-04-27
US7943661B2 (en) 2011-05-17
IL165696A0 (en) 2006-01-15
FR2841900A1 (fr) 2004-01-09
PT1525177E (pt) 2007-09-06
CA2490986C (fr) 2012-09-18
PL207362B1 (pl) 2010-12-31
DE60314633D1 (de) 2007-08-09
NO20045301L (no) 2005-02-04
BRPI0312398B1 (pt) 2016-11-08
DK1525177T3 (da) 2007-10-22
EA200500169A1 (ru) 2005-06-30
CN1668565A (zh) 2005-09-14
ZA200501082B (en) 2007-01-31

Similar Documents

Publication Publication Date Title
BRPI0312398B8 (pt) derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0309964A (pt) Derivados anticonvulsivos de sulfamoto substituìdo
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. C07C 51/00, C07C 67/00, C07C 59/90, C07C 59/88, C07C 59/84, C07C 69/712, C07C 69/736,C07C 69/738, C07C 69/67, C07C 251/48, C07C 323/63, C07C 281/00, C07C 323/09, A61P 9/00, A61P 9/10

Ipc: C07C 51/00 (2011.01), C07C 67/00 (2011.01), C07C 5

Free format text: PARA:INT.CI. C07C 51/00, C07C 67/00, C07C 59/90, C07C 59/88, C07C 59/84, C07C 69/712, C07C 69/736, C07C 69/738, C07C 69/67, C07C 251/48, C07C 323/63, C07C 281/00, C07C 323/09, A61P 9/00, A61P 9/10

Ipc: C07C 51/00 (2011.01), C07C 67/00 (2011.01), C07C 5

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07C 51/00 , C07C 67/00 , C07C 59/90 , C07C 59/88 , C07C 59/84 , C07C 69/712 , C07C 69/736 , C07C 69/738 , C07C 69/67 , C07C 251/48 , C07C 323/63 , C07C 323/61 , C07C 323/64 , C07C 281/00 , C07C 323/09 , A61P 9/00 , A61P 9/10

Ipc: A61K 31/192 (2006.01), A61K 31/352 (2006.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]

Free format text: REFERENTE A RPI 2385, DE 20/09/2016

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/11/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.